BioSpace News Archive

Echosens, a high-technology company offering the FibroScan family of products, announces its presentation (K7), “Modeling the Return on Investment of VCTE for Fatty Liver Disease (FLD) in a General Population Incorporating Device Costs,” at the Academy of Managed Care Pharmacy’s (AMCP) virtual meeting, April 12 - 16, 2021.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). CSA is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias

Senti Bio, a leading gene circuit company, today announced that results from its discovery-stage oncology program using allogeneic CAR-NK cells were presented during a poster session at the American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10, 2021.

Initial safety data expected from CAReS Study before end of 2021 Targeting multi-billion market with no approved therapies for cancer-related anorexia

Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock , (ii) 7,671,937 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,671,937 shares of common stock

Cytokine data from cancer patients reveal a unique profile for AMV564 therapy, with strong induction of IFNγ and other cytokines and chemokines that drive T cell activation and trafficking, and limited levels of IL6. As MDSC produce IL6 and other cytokines that promote cytokine release syndrome (CRS), these findings are consistent with our observations of limited CRS with AMV564 treatment.

Philogen S.p.A. is pleased to announce a publication describing the construction of a DNA-encoded chemical library that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of its Phase 1/2 FORGE-1 study of TPX-0131, a potent inhibitor of the anaplastic lymphoma kinase (ALK) and multiple resistant mutations of ALK.

Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced that Luis Peña, president and chief executive officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021, at 11:15 a.m. PDT/2:15 p.m. EDT.

Modern Vascular, a trailblazing medical group dedicated to preventing amputation through the outpatient treatment of Peripheral Artery Disease with a headquarters in Phoenix, announced Carl Scotten as Modern Vascular’s Vice President of National Sales and Strategic Alliances, a newly created position.